According to the research report titled ‘GLOBAL LIQUID BIOPSY MARKET 2021-2028,’ available with MarketStudyReport, global liquid biopsy market is expected to grow at 18.54% CAGR during 2021-2028. 

High prevalence of cancer among the geriatric population, supportive government policies, and rising importance of liquid biopsy testing are factors propelling the growth of global liquid biopsy market. 

Moreover, massive advancements in technologies, soaring demand for diagnostic centers, and unexplored opportunities in developing nations act as avenues for stakeholders to invest in and gain profits during the forecast period.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3754634/  

On the contrary, dearth of skilled professionals, lack of reimbursement policies, and various disadvantages associated with compensation schemes are likely to impede the progress of the industry in the coming years. 

In terms of clinical application, the business sphere is categorized into diagnosis & screening, treatment monitoring, treatment selection, and prognosis & reoccurrence monitoring. With respect to analysis platform, the business environment is segregated into PCR (polymerase chain reaction), proteomics, NGS (next-generation sequencing), microarray, and others. 

Based on therapeutic application, the market is segmented into melanoma cancer, lung cancer, prostate cancer, breast cancer, colorectal cancer, non-oncology application, and others. By biomarker type, worldwide liquid biopsy industry is classified into cells, nucleic acid, protein, and extracellular vesicles.

Considering analysis purpose, the industry is divided into diagnosis, early detection/screening, monitoring, and therapy guidance. By product type, the market is divided into circulating tumor cells (CTCS), extracellular vesicles, cell-free DNA (CFDNA), circulating tumor DNA (CTDNA), and others

In terms of industry verticals, the business sphere is categorized into clinical diagnostic laboratories, physicians' office laboratories, and hospitals.

From a geographical standpoint, Asia Pacific market is poised to exhibit a notable growth rate during the projected timeline attributed to the huge population base in countries like China and India which is boosting the demand for the product. Additionally, an increase in healthcare spending, rising awareness about liquid biopsy are further accelerating industry development across the region. 

Prominent players in global liquid biopsy industry include Natera Inc., Menarini-Silicon Biosystems S.p.A, F Hoffmann-La Roche AG, Qiagen N.V., Angle plc, Biocept Inc., Becton Dickinson and Company (BD), Illumina Inc., Grail Inc., Myriad Genetics Inc., MDxHealth SA, Bio-Rad Laboratories Inc., Adaptive Biotechnologies Corporation, Guardant Health Inc., Thermo Fisher Scientific Inc., Foundation Medicine, Agilent Technologies Inc, and Personal Genome Diagnostics Inc. among others.